Arrowhead Collaboration presents Phase IIb data from Hepatitis B study

Arrowhead Pharmaceuticals Inc collaborator, Janssen Pharmaceuticals Inc, have presented clinical data from REEF-1, a Phase IIb study of different combination regimens. This included JNJ-73763989, formerly called ARO-HBV, and a nucleostide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB).

read more